PLoS ONE (Jan 2018)

Initial validation of a simulation model for estimating the impact of serogroup A Neisseria meningitidis vaccination in the African meningitis belt.

  • Michael L Jackson,
  • Alpha Oumar Diallo,
  • Isaie Médah,
  • Brice Wilfried Bicaba,
  • Issaka Yaméogo,
  • Daouda Koussoubé,
  • Rasmata Ouédraogo,
  • Lassané Sangaré,
  • Sarah A Mbaeyi

DOI
https://doi.org/10.1371/journal.pone.0206117
Journal volume & issue
Vol. 13, no. 10
p. e0206117

Abstract

Read online

We previously developed a mathematical simulation of serogroup A Neisseria meningitidis (NmA) transmission in Burkina Faso, with the goal of forecasting the relative benefit of different vaccination programs. Here, we revisit key structural assumptions of the model by comparing how accurately the different assumptions reproduce observed NmA trends following vaccine introduction. A priori, we updated several of the model's parameters based on recently published studies. We simulated NmA disease under different assumptions about duration of vaccine-induced protection (including the possibility that vaccine-induced protection may last longer than natural immunity). We compared simulated and observed case counts from 2011-2017. We then used the best-fit model to forecast the impact of different vaccination strategies. Our updated model, with the assumption that vaccine-induced immunity lasts longer than immunity following NmA colonization, was able to reproduce observed trends in NmA disease. The updated model predicts that, following a mass campaign among persons 1-29 years of age, either routine immunization of 9 month-old children or periodic mini-campaigns among children 1-4 years of age will lead to sustained control of epidemic NmA in Burkina Faso. This validated model can help public health officials set policies for meningococcal vaccination in Africa.